Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
Clinical trial NCT03468751 · UNKNOWN
Trial details
- NCT number
- NCT03468751
- Sponsor
- Henlix, Inc
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-14
- Primary completion
- 2020-06-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.